ARS Pharmaceuticals Inc
SPRY
View Detailed Chart
13.060USD
+2.110+19.27%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
1.29BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+19.27%
5 Days
+13.66%
1 Month
+31.52%
6 Months
-27.04%
Year to Date
+12.10%
1 Year
+14.26%
View Detailed Chart
TradingKey Stock Score of ARS Pharmaceuticals Inc
Currency: USD Updated: 2026-01-09Key Insights
ARS Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 19 out of 396 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 27.83.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ARS Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
ARS Pharmaceuticals Inc Highlights
StrengthsRisks
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 6674.24% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 89.15M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -16.23, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 85.62M shares, decreasing 11.05% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 147.00K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.06.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
27.833
Target Price
+153.72%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ARS Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ARS Pharmaceuticals Inc Info
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Ticker SymbolSPRY
CompanyARS Pharmaceuticals Inc
CEOLowenthal (Richard E)
Websitehttps://ars-pharma.com/
FAQs
What is the current price of ARS Pharmaceuticals Inc (SPRY)?
The current price of ARS Pharmaceuticals Inc (SPRY) is 13.060.
What is the symbol of ARS Pharmaceuticals Inc?
The ticker symbol of ARS Pharmaceuticals Inc is SPRY.
What is the 52-week high of ARS Pharmaceuticals Inc?
The 52-week high of ARS Pharmaceuticals Inc is 18.900.
What is the 52-week low of ARS Pharmaceuticals Inc?
The 52-week low of ARS Pharmaceuticals Inc is 6.660.
What is the market capitalization of ARS Pharmaceuticals Inc?
The market capitalization of ARS Pharmaceuticals Inc is 1.29B.
What is the net income of ARS Pharmaceuticals Inc?
The net income of ARS Pharmaceuticals Inc is 8.00M.
Is ARS Pharmaceuticals Inc (SPRY) currently rated as Buy, Hold, or Sell?
According to analysts, ARS Pharmaceuticals Inc (SPRY) has an overall rating of --, with a price target of 27.833.
What is the Earnings Per Share (EPS TTM) of ARS Pharmaceuticals Inc (SPRY)?
The Earnings Per Share (EPS TTM) of ARS Pharmaceuticals Inc (SPRY) is -0.805.
Related Instruments
-1.97%
-0.66%
-1.74%
+0.68%
-0.43%
+0.05%
+2.58%
-1.21%
+0.36%
+0.71%
+1.87%
-1.24%
-0.05%
+0.31%
+0.24%
-1.34%
-0.56%
0.00%
+0.25%
-0.28%Popular Symbols
